沙夫拉纳尔对抗糖尿病和内皮功能障碍的作用 沙夫拉纳尔对抗糖尿病和内皮功能障碍的作用 沙夫拉纳尔对抗糖尿病和内皮功能障碍的作用 Streptozotocin诱导的糖尿病大鼠
Ayten Demirci1,2, Ayse Saide Sahin3, Burak Cem Soner4
1Department of Pharmacy, Konya City Hospital, Konya, Türkiye. eczaytendemirci@gmail.com.
Molecular biology reports
|July 21, 2025
概括
沙夫兰是沙夫兰的一种化合物,在糖尿病老鼠中有效降低血糖和HbA1c. 它还显示出保护糖尿病相关的内皮功能障碍的潜力,提供了一个有前途的自然治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 自然产品化学 自然产品化学
背景情况:
- 糖尿病管理通常依赖于口服低血糖药物,具有潜在的不良影响.
- 草药正在探索更有效,更安全的糖尿病治疗方法.
- 沙夫兰提取物,特别是其活性化合物沙夫兰,表现出有前途的抗糖尿病特性.
研究的目的:
- 为了研究沙夫兰的抗糖尿病潜力.
- 为了评估萨夫拉纳尔对糖尿病诱导的内皮损伤的保护作用.
主要方法:
- 一个糖尿病模型被诱导在雄性Wistar白色老鼠使用链毒素.
- 萨夫拉纳尔用三种不同的剂量给药.
- 评估了血糖,HbA1c,胰岛素水平和基因表达 (VCAM-1, eNOS).
- 进行了胰腺和大动脉组织的免疫组织化学分析.
- 评估了血管放松剂的反应.
主要成果:
- 沙夫兰醇显著降低了血糖和HbA1c水平,以剂量依赖的方式.
- 胰岛素水平和胰岛素抗体在胰腺组织中的染色在沙夫兰治疗时增加.
- 沙夫兰醇降低了VCAM-1,并在大动脉组织中增加了eNOS基因表达.
- 在孤立的器官浴中,乙胆诱导的放松反应得到了改善.
结论:
- 沙夫兰醇具有显著的抗糖尿病特性.
- 沙夫拉纳显示出减轻糖尿病诱导的内皮功能障碍的潜力.
- 沙夫拉那尔代表了一种有前途的天然化合物,用于管理糖尿病及其并发症.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305
01:17Oral Hypoglycemic Agents: Sulfonylureas
342
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
342
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
265
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
265